VAXESS PRESENTS DATA ON DEVELOPMENT OF NEEDLE-FREE, SELF-APPLIED MICROARRAY PATCH FOR GLP-1 DELIVERY

WOBURN, Mass, June, 23, 2025 — Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, is presenting new preclinical data at the 2025 American Diabetes Association (ADA) Scientific Sessions in Chicago. Vaxess’s research demonstrates that the company’s microarray patch (MAP) is capable of delivering semaglutide, a GLP-1 receptor agonist, with bioavailability comparable to subcutaneous injection.

“In recent years GLP-1 therapies have shown they are extremely effective for metabolic disease, and the next step forward for the GLP-1 industry will be finding meaningful ways of improving the patient experience,” said Rachel Sha, CEO of Vaxess. “At Vaxess, we are developing a needle-free, shelf-stable, self-applied microarray patch as a new mode of administering GLP-1 therapies. Moving to patch-based GLP-1 delivery has the potential to both increase GLP-1 access and improve adherence to treatment plans”

At ADA Scientific Sessions, Vaxess is presenting its evaluation of semaglutide delivery in Gottingen minipigs, a widely-used preclinical model for intradermal drug delivery. Vaxess tested two patch designs, each delivering a clinically-relevant 2 nmol/kg dose. Both designs demonstrated bioavailability comparable to subcutaneous injection and achieved modestly higher Cmax, with similar half-life profiles.

“In a clinically relevant model, using a clinically relevant dose, bioavailability is comparable for  delivery of semaglutide through Vaxess’s microarray patches and subcutaneous injection,” said Lynda Tussey, PhD, chief development officer at Vaxess. “Vaxess’s microarray patch is a promising alternative mode of delivery. with the potential to address treatment hesitancy and adherence."  

This work was supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). To learn more about Vaxess’s ADA presentation, download the presentation poster.

About Vaxess

Vaxess Technologies is transforming home delivery of next generation therapies.

Vaxess's platform combines a proprietary microarray patch and applicator, capable of delivering a wide range of therapies. Advanced biomaterials used for the dissolvable microarray tips enable the greatest levels of dose delivery control, and can be modified to deliver different payloads. Additionally, the patch does not require refrigeration, enabling delivery to low resource settings.

Vaxess has raised more than $100 million in grant and venture capital funding from groups such as RA Capital Management, Engine Ventures, GHIC, Mission BioCapital, BARDA, DARPA, NIH, NSF and the Gates Foundation. The company has also generated strong clinical and in-vivo proof of concept in the platform with a wide range of molecules. For more information, please visit the company website at www.vaxess.com or send additional inquiries to contact@vaxess.com.